Clinical Trials Browser

Phase 1/2 × Interleukin-12 × 90 days × Clear all

NCT01468896 2026-04-29

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

23 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck